Adipotide is a peptidomimetic compound designed to selectively target blood vessels within white adipose tissue by binding to prohibitin‑1 on the vascular endothelium^[2][8]. Once bound, it delivers a pro‑apoptotic sequence that triggers vessel destruction, cutting off the blood supply to fat cells and causing them to undergo apoptosis and be metabolized^[1][2]. Preclinical studies in obese rodents demonstrated approximately 30% body weight reduction, and obese primates showed about 11% weight loss after 4 weeks of treatment^[1][9]. A first‑in‑human Phase 1 trial was initiated in obese cancer patients^[3], but further clinical development was discontinued due to strategic and safety reasons, including reversible renal effects observed at higher doses^[4].

Observations from preclinical literature and limited human data.

• Preclinical studies showed notable targeted fat mass reduction (up to 30% body weight in rodents, ~11% in primates over 4 weeks)^[1][2][8][9].
• Mechanism specifically targets adipose tissue vasculature, sparing other tissues in preclinical models^[2].
• Safety concerns: Clinical development was discontinued due to safety issues^[3][4]; reversible kidney toxicity was dose‑dependent in preclinical studies^[1].
• Mild injection‑site reactions (redness, swelling) may occur with subcutaneous administration.
• Limited human data: Only Phase 1 trial data available; long‑term safety profile in humans is unknown.

Complementary strategies for best outcomes.

• Pair with a balanced, protein‑forward diet tailored to energy needs.
• Combine resistance training and aerobic activity to reinforce metabolic adaptations.
• Prioritize sleep and stress management to support adherence and recovery.
• Monitor kidney function if extending beyond initial 4‑week cycle due to preclinical observations of renal effects.